Alahmadi, Alaa, Alotibi, Reem, Chan, Yee-Hung, Taha, Sarab, Rifqi, Daniah, Alshehri, Nouf, Alalawi, Sulaiman, Alradi, Fahad, Gibbs, Alex, Hughes, Timothy  ORCID: https://orcid.org/0000-0003-2348-3490 and Ramji, Dipak ORCID: https://orcid.org/0000-0002-6419-5578
2026.
Resveratrol mediates anti-atherogenic actions in vitro and in LDL receptor-deficient mice fed a high fat diet via antioxidant, anti-inflammatory and plaque stabilising activities.
Antioxidants
15
(1)
, 76.
10.3390/antiox15010076
|
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (4MB) | Preview |
Abstract
Current pharmacotherapies against atherosclerotic cardiovascular disease are associated with considerable residual risk, together with various adverse side effects. Nutraceuticals, such as resveratrol (RSV), with excellent safety profile, represent promising alternatives and potential treatment. However, the full spectrum of anti-atherogenic actions regulated by RSV and the underlying molecular mechanisms remain poorly understood. The objective of this study therefore was to investigate the impact of RSV on key atherosclerosis-associated processes in monocytes, macrophages, endothelial cells, and smooth muscle cells in vitro, as well as in LDL receptor-deficient mice fed a high-fat diet in vivo. RSV produced beneficial changes in the plasma lipid profile and peripheral blood lymphoid cells in vivo. RSV also attenuated plaque inflammation by decreasing macrophage and T cell content and enhanced markers of plaque stability, with increased levels of smooth muscle cells and collagen content. In vitro, RSV inhibited chemokine-driven monocyte migration, inflammasome activation, matrix metalloproteinase activity, pro-inflammatory gene expression, reactive oxygen species production, and smooth muscle cell invasion. RNA-sequencing of the thoracic aorta revealed key genes and pathways mediating the antioxidant, anti-inflammatory and plaque-stabilising activities of RSV. These studies provide novel mechanistic insights on the anti-atherogenic actions of RSV and support further evaluation in human clinical trials.
| Item Type: | Article |
|---|---|
| Date Type: | Published Online |
| Status: | Published |
| Schools: | Schools > Medicine Schools > Biosciences Research Institutes & Centres > European Cancer Stem Cell Research Institute (ECSCRI) |
| Publisher: | MDPI |
| ISSN: | 2076-3921 |
| Date of First Compliant Deposit: | 6 January 2026 |
| Date of Acceptance: | 24 December 2025 |
| Last Modified: | 08 Jan 2026 10:07 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/183550 |
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric